Health
QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial – OncLive
Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Quality of life (QoL) according to patient-reported outcomes (PROs) was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib (Zejula) versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial, according to a subanalysis presented by Bhavana Pothuri, MD, during the ESMO 2020 Virtual Congress.
PRIMA was an ongoing a randomized, double-blind, placebo-controlled phase 3 trial in which patients with newly diagno…
-
Noosa News16 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business18 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400
-
Business19 hours agoWhy you should sell CBA, Lynas, and Tabcorp shares today
-
Noosa News18 hours agoBrisbane news live: 80,000 green bins rolled out | Residents told to prepare for ‘violent’ summer storms | Council declares water safe for swimming despite dead fish